Introduction/Background The aim of the study was to compare the effectiveness of neoadjuvant chemotherapy regimens (NACT): Mitomycin and Cisplatin (MP) vs Paclitaxel and Cisplatin/Carboplatin (TCb/TP) in advanced BRCA1-mutated ovarian cancer (BMOC).
Methodology In a prospective cohort of 13 patients (38–66 years (mean age 52 years) we analyzed the efficacy of Mitomycin (10 mg/m2) and Cisplatin (100 mg/m2) NACT administered intravenously every 3–4 weeks. The control group included 22 patients of retrospective cohort (38–67 years (mean age 51,9 years), who received standard 1-st line NACT (TCb/TP). Clinical efficacy was evaluated according to RECIST 1.1, histopathologic response - according to the Bohm scale (2015).
Results The objective response was observed in 13/13 (100%) patientsin MP group vs 9/22 (41%) patientsin TCb/TP group (p=0,0006). Complete surgical cytoreduction was achieved in all patients (13/13; 100%) after MP vs 13/22 (59%) cases in TCb/TP group (p=0,01). Complete pathological response was confirmed only in MP group - in 3 out of 13 patients (23%) vs 0/22 patients (0%) in TCb/TP group (p=0,04).
Conclusion The short-term results of the present study showed that the neoadjuvant chemotherapy with Cisplatin and Mitomycin is an effective option for BRCA1-associated advanced ovarian cancer treatment.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.